

IFW

PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Yanhong Zhu et al.)
) Art Unit: 1646
Serial No. 10/650,110)
) Examiner: Not yet assigned
Filed: August 26, 2003)


For: A Method of Treating and Preventing Alzheimer Disease Through Administration
Of Delipidated Protein and Lipoprotein Particles

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with
the United States Postal Service as first class mail in an envelope
addressed to: Mail Stop Amendment, Commissioner for Patents,
P.O. Box 1450, Alexandria, VA 22313-1450, on August 16, 2004



Matthew L. Collins

Sir:


The citation of information on the attached Form PTO/SB/08 is made pursuant to
37 C.F.R. §§ 1.56, 1.97, and 1.98. A copy of each Non-U.S. Patent cited item is enclosed.

The citation of this information does not constitute an admission of priority or that
any cited item is available as a reference, or a waiver of any right the applicant may have under
applicable statutes, Rules of Practice in patent cases, or otherwise.

Respectfully submitted,


John K. McDonald, Ph.D.
Reg. No. 42,830

KILPATRICK STOCKTON LLP
1100 Peachtree Street, Suite 2800
Atlanta, Georgia 30309-4530
(404) 815-6500
Our Docket: 13131-0292 (44378/287574)



Substitute for Form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0292 (44378/287574)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	1	3,647,624		Evenson	03-07-1972	
	2	3,958,939		Jones	05-25-1976	
	3	3,983,008		Shinozaki et al.	09-28-1976	
	4	3,989,466		Pan	11-02-1976	
	5	4,025,423		Stonner et al.	05-24-1977	
	6	4,103,685		Lupien et al.	08-01-1978	
	7	4,124,509		Iijima et al.	11-07-1978	
	8	4,234,317		Lucas et al.	11-18-1980	
	9	4,235,602		Meyer et al.	11-25-1980	
	10	4,258,010		Rozsa et al.	03-24-1981	
	11	4,350,156		Malchesky et al.	09-21-1982	
	12	4,391,711		Jackson et al.	07-05-1983	
	13	4,399,217		Holmquist et al.	08-16-1983	
	14	4,402,940		Nose et al.	09-16-1983	
	15	4,435,289		Breslau	03-06-1984	
	16	4,463,988		Bouck et al.	08-07-1984	
	17	4,481,189		Prince	11-06-1984	
	18	4,522,809		Adamowicz et al.	06-11-1985	
	19	4,540,401		Marten	09-10-1985	
	20	4,540,573		Neurath et al.	09-10-1985	
	21	4,591,505		Prince	05-27-1986	
	22	4,613,501		Horowitz	09-23-1986	
	23	4,615,886		Purcell et al.	10-07-1986	
	24	4,643,718		Marten	02-17-1987	
	25	4,645,512		Johns	02-24-1987	
	26	4,647,280		Maaskant et al.	03-03-1987	
	27	4,648,974		Roskopf et al.	03-10-1987	
	28	4,668,398		Silvis	05-26-1987	
	29	4,671,909		Torobin	09-09-1987	
	30	4,676,905		Nagao et al.	06-30-1987	
	31	4,677,057		Curtiss et al.	06-30-1987	
	32	4,680,320		Uku et al.	07-14-1987	
	33	4,696,670		Ohnishi et al.	09-29-1987	
	34	4,775,483		Mookerjee et al.	10-04-1988	
	35	4,832,034		Pizziconi et al.	05-23-1989	
	36	4,836,928		Aoyagi et al.	06-06-1989	
	37	4,879,037		Utzing	11-07-1989	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646
		Examiner Name	Not yet Assigned
Sheet 2 of 9	Attorney Docket Number		13131-0292 (44378/287574)

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	38	4,895,558		Cham	01-23-1990	
	39	4,908,354		Seidel et al.	03-13-1990	
	40	4,909,940		Horowitz et al.	03-20-1990	
	41	4,909,942		Sato et al.	03-20-1990	
	42	4,923,439		Seidel et al.	05-08-1990	
	43	4,935,204		Seidel et al.	06-19-1990	
	44	4,966,709		Nose et al.	10-30-1990	
	45	4,970,144		Fareed et al.	11-13-1990	
	46	5,026,479		Bikson et al.	06-25-1991	
	47	5,080,796		Nose et al.	01-14-1992	
	48	5,089,602		Islaker et al.	02-18-1992	
	49	5,112,956		Tang et al.	05-12-1992	
	50	5,116,307		Collins	05-26-1992	
	51	5,126,240		Curtiss	03-30-1992	
	52	5,128,318		Levine et al.	07-07-1992	
	53	5,152,743		Gorsuch et al.	10-06-1992	
	54	5,187,010		Parham et al.	02-16-1993	
	55	5,203,778		Boehringer	04-20-1993	
	56	5,211,850		Shettigar et al.	05-18-1993	
	57	5,236,644		Parham et al.	08-17-1993	
	58	5,256,767		Salk et al.	10-26-1993	
	59	5,258,149		Parham et al.	11-02-1993	
	60	5,279,540		Davidson	01-18-1994	
	61	5,301,694		Raymond et al.	04-12-1994	
	62	5,354,262		Boehringer et al.	10-11-1994	
	63	5,391,143		Kensey	02-21-1995	
	64	5,393,429		Nakayama et al.	02-28-1995	
	65	5,401,415		Rauh et al.	03-28-1995	
	66	5,401,466		Foltz et al.	03-28-1995	
	67	5,418,061		Parham et al.	05-23-1995	
	68	5,419,759		Naficy	05-30-1995	
	69	5,424,068		Filip	06-13-1995	
	70	5,476,715		Otto	12-19-1995	
	71	5,484,396		Naficy	01-16-1996	
	72	5,496,637		Parham et al.	03-05-1996	
	73	5,523,096		Okarma et al.	06-04-1996	
	74	5,634,893		Rishton	06-03-1997	
	75	5,637,224		Sirkar et al.	06-10-1997	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646
		Examiner Name	Not yet Assigned
Sheet 3 of 9	Attorney Docket Number	13131-0292 (44378/287574)	

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			
	76	5,652,339		Lerch et al.	07-29-1997	
	77	5,679,260		Boos et al.	10-21-1997	
	78	5,698,432		Oxford	12-16-1997	
	79	5,707,673		Prevost et al.	01-13-1998	
	80	5,719,194		Mann et al.	02-17-1998	
	81	5,744,038		Cham	04-28-1998	
	82	5,753,227		Strahilevitz	05-19-1998	
	83	5,853,725		Salk et al.	12-29-1998	
	84	5,855,782		Falkenhagen et al.	01-05-1999	
	85	5,858,238		McRea et al.	01-12-1999	
	86	5,877,005		Castor	03-02-1999	
	87	5,885,578		Salk et al.	03-23-1999	
	88	5,895,650		Salk et al.	04-20-1999	
	89	5,911,698		Cham	06-15-1999	
	90	5,916,806		Salk et al.	06-29-1999	
	91	5,919,369		Ash	07-06-1999	
	92	5,928,930		Salk et al.	07-27-1999	
	93	5,948,441		Lenk et al.	09-09-1999	
	94	5,962,322		Kozarsky et al.	10-05-1999	
	95	5,980,478		Gorsuch et al.	11-09-1999	
	96	6,004,925		Dasseux et al.	12-21-1999	
	97	6,017,543		Salk et al.	01-25-2000	
	98	6,022,333		Kensev	02-28-2000	
	99	6,037,323		Dasseux et al.	03-14-2000	
	100	6,039,946		Strahilevitz	03-21-2000	
	101	6,046,166		Dasseux et al.	04-04-2000	
	102	6,136,321		Barrett et al.	10-24-2000	
	103	6,139,746		Kopf	10-31-2000	
	104	6,156,727		Garber et al.	12-05-2000	
	105	6,171,373		Park et al.	01-09-2001	
	106	6,193,891		Kent et al.	02-27-2001	
	107	6,264,623		Strahilevitz	07-24-2001	
	108	6,309,550		Iverson et al.	10-30-2001	
	109	6,337,368		Kobayashi et al.	01-08-2002	
	110	6,605,588		Lees et al.	08-12-2003	
	111	6,706,008		Vishnoi et al.	03-16-2004	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/A/PTO <h1>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h1> (use as many sheets as necessary)				Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.	
				Complete if Known	
				Application Number	10/650,110
				Filing Date	August 26, 2003
				First Named Inventor	Yanhong Zhu
				Group Art Unit	1646
				Examiner Name	Not yet Assigned
Sheet	4	of	9	Attorney Docket Number	13131-0292 (44378/287574)

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646
		Examiner Name	Not yet Assigned
Sheet 5	of 9	Attorney Docket Number	13131-0292 (44378/287574)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	129	Agnese, et al., Clinical Biochemistry, Evaluation of Four Reagents for Delipidation of Serum, 16, 98-100. (1983)	
	130	Albouz, et al., Ann. Biol. Clin., Extraction of Plasma Lipids Preserving Antigenic Properties of Proteins and Allowing Quantitation of Gangliosides by Neuraminic Acid Determination, 37, 287-290. (abstract only) (1979)	
	131	Andre et al., Journal of Virology, Characterization of Low- and Very-Low-Density Hepatitis C Virus RNA-Containing Particles, 76 (14), 6919-6928. (July 2002)	
	132	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Distribution of Apo A-I-Containing HDL Subpopulations in Patients with Coronary Heart Disease, 2670-2676. (December 1, 2000)	
	133	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Presence and Formation of 'Free Apolipoprotein A-I-Like' Particles in Human Plasma, 15, 1419-1423. (1995)	
	134	Asztalos et al., Arterioscler. Thromb. Vasc. Biol., Role of Free Apolipoprotein A-I in Cholesterol Efflux, 17, 1630-1636. (1997)	
	135	Badimon, et al., Laboratory Investigation, High Density Lipoprotein Plasma Fractions Inhibit Aortic Fatty Streaks in Cholesterol-Fed Rabbits, 60, 455-461. (1989)	
	136	Badimon, et al., J. Clinical Investigation, Regression of Atherosclerotic Lesions by High Density Lipoprotein Plasma Fraction in the Cholesterol-Fed Rabbit, 85, 1234-1241. (1990)	
	137	Barrans et al., Biochimica et Biophysica Acta, Pre-β HDL: Structure and Metabolism, 1300, 73-85. (1996)	
	138	Bloom, et al., Clin. Biochem., Quantitation of lipid profiles from isolated serum lipoproteins using small volumes of human serum, 14, 119-125. (abstract only) (June 1981)	
	139	Cham, Clinical Chemistry, Nature of the Interaction Between Low-Density Lipoproteins and Polyanions and Metal Ions, as Exemplified by Heparin and Ca ²⁺ , 22, 1812-1816. (1976)	
	140	Cham, et al., J. of Lipid Research, A Solvent System for Delipidation of Plasma or Serum Without Protein Precipitation, 17, 176-181. (1976)	
	141	Cham, et al., Clinical Chemistry, Changes in Electrophoretic Mobilities of α- and β-Lipoproteins as a Result of Plasma Delipidation, 22, 305-309. (1976)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646
		Examiner Name	Not yet Assigned
Sheet 6	of 9	Attorney Docket Number	13131-0292 (44378/287574)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	142	Cham, et al., Biochemical and Biophysical Research Communications, Heterogeneity of Lipoprotein B, 103, 196-206. (1981)	
	143	Cham, et al., Chem. Biol. Interactions, Importance of Apolipoproteins in Lipid Metabolism, 20, 263-277. (1978)	
	144	Cham, et al., J. Biol. Chem., In Vitro Partial Relipidation of Apolipoproteins in Plasma, 251, 6367-6371. (abstract only) (1976)	
	145	Cham, et al., Pharmacol. (Life Sci. Adv.), Lipid Apheresis in an Animal Model Causes Acute Reduction in plasma Lipid Concentrations and Mobilisation of Lipid from Liver and Aorta, 13, 25-32. (1994)	
	146	Cham, et al., J. Clin. Apheresis, Lipid Apheresis in an Animal Model Causes In Vivo Changes in Lipoprotein Electrophoretic Patterns, 11, 61-70. (1996)	
	147	Cham, et al., J. Clin. Apheresis, Lipid Apheresis: An In Vivo Application of Plasma Delipidation with Organic Solvents Resulting in Acute Transient Reduction of Circulating Plasma Lipids in Animals, 10, 61-69. (1995)	
	148	Cham, et al., Clinical Chemistry, Phospholipids in EDTA - Treated Plasma and Serum, 39, 2347-2348. (1993)	
	149	Cham, et al., 59th Congress European Atherosclerosis Society, Nice, France, Rapid Regression of Atherosclerosis by Cholesterol Apheresis - A Newly Developed Technique, 17-21. (abstract only) (May 1992)	
	150	Cham, et al., Clinica Chimica Acta, Rapid, Sensitive Method for the Separation of Free Cholesterol from Ester Cholesterol, 49, 109-113. (1973)	
	151	Collet et al., Journal of Biological Chemistry, Differential Effects of Lecithin and Cholesterol on the Immunoreactivity and Confirmation of Apolipoprotein A-I in High Density Lipoproteins, 266 (14), 9145-9152. (May 15, 1991)	
	152	Cruzado et al., Analytical Biochemistry, Characterization and Quantitation of the Apoproteins of High-Density Lipoprotein by Capillary Electrophoresis, 14 (7), 100-109. (1996)	
	153	Deva, et al., J. Hosp. Infect., Establishment of an in-use testing method for evaluating disinfection of surgical instruments using the duck hepatitis B model, 22, 119-130. (abstract only) (June 1996)	
	154	Dwivedy, 18th Australian Atherosclerosis Society Conference, Surfers Paradise, Increase of Reverse Cholesterol Transport by Cholesterol Apheresis Regression of Atherosclerosis, 21. (1992)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/650,110
		Filing Date	August 26, 2003
		First Named Inventor	Yanhong Zhu
		Group Art Unit	1646
		Examiner Name	Not yet Assigned
Sheet 7	of 9	Attorney Docket Number	13131-0292 (44378/287574)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	155	Eisenhauer, et al, Klin Wochenschr (KWH), Selective Removal of Low Density Lipoproteins (LDL) by Precipitation at Low pH: First Clinical Application of the HELP System, 65, 161-168. (1987)	
	156	Fang, et al., 18th Australian Atherosclerosis Society Conference, Gold Coast, Australia, In Vivo Rapid Mobilization of Adipose Tissue by Lipid Apheresis - A Newly Developed Technique. (1992)	
	157	Feinstone, et al., Infection and Immunity, Inactivation of Hepatitis B Virus and Non-A, Non-B Hepatitis by Chloroform, 41, 816-821. (August 1983)	
	158	Hatch et al., Lipoprotein Analysis, Advances in Lipid Research, Practical Methods for Plasma Lipoprotein Analysis, 6, 1-68. (1968)	
	159	Horowitz, et al., Blood Coagulation and Fibrinolysis, Viral safety of solvent/detergent-treated blood products, 5, S21-S28. (1994)	
	160	Innerarity, et al., Biochemistry, Enhanced Binding by Cultured Human Fibroblasts of Apo-E-Containing Lipoproteins as Compared with Low Density Lipoproteins, 17, 1440-1447. (1978)	
	161	Jackson et al., Biochimica et Biophysica Acta, Isolation and Characterization of the Major Apolipoprotein from Chicken High Density Lipoproteins, 420, 342-349. (1976)	
	162	Klimov, et al., Kardologia, Extraction of Lipids from Blood Plasma and Subsequent Introduction of Autologous Delipidized Plasma into the Body as a Possible Means to Treat Atherosclerosis [translation], 18, 23-29. (1978)	
	163	Koizumi, et al., J. Lipid Research, Behavior of Human Apolipoprotein A-1: Phospho-Lipid and apoHDL: Phospholipid Complexes In Vitro and After Injection into Rabbits, 29, 1405-1415. (1988)	
	164	Kostner, et al., XI Internet Symp. on Drugs Affecting Lipid Metabolism, Italy, Increase of APO A1 Concentration in Hypercholesterolaemic Chickens after Treatment with a Newly Developed Extracorporeal Lipid Elimination, (May 13, 1992)	
	165	Kostner, et al., European Journal of Clinical Investigation, Lecithin-cholesterol acyltransferase activity in Normocholesterolaemic and Hypercholesterolaemic Roosters: Modulation by Lipid Apheresis, 27, 212-218. (May 7, 1997)	
	166	Lupien, et al., Lancet (LOS), A New Approach to the Management of Familial Hypercholesterolaemia: Removal of Plasma-Cholesterol Based on the Principle of Affinity Chromatography, 1, 1261-1265. (1976)	
	167	Moya et al., Arteriosclerosis and Thrombosis, A Cell Culture System for Screening Human Serum for Ability to Promote Cellular Cholesterol Efflux, 14 (7), 1056-1065. (July 1994)	

Examiner Signature	Date Considered
--------------------	-----------------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/650,110
				Filing Date	August 26, 2003
				First Named Inventor	Yanhong Zhu
				Group Art Unit	1646
				Examiner Name	Not yet Assigned
Sheet	8	of	9	Attorney Docket Number	13131-0292 (44378/287574)

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	168	Ngu, Medical Hypotheses, Chronic Infections from the Perspective of Evolution: a Hypothesis, 42, 81-88. (1994)	
	169	Ngu, Medical Hypotheses, Human Cancers and Viruses: A Hypothesis for Immune Destruction of Tumours Caused by Certain Enveloped Viruses Using Modified Viral Antigens, 39, 17-21. (1992)	
	170	Ngu, Medical Hypotheses, The viral envelope in the evolution of HIV: a hypothetical approach to inducing an effective immune response to the virus, 48, 517-521. (1997)	
	171	Okazaki et al., Journal of Chromatography, Biomedical Applications, Improved High-Performance Liquid Chromatographic Method for the Determination of Apolipoproteins in Serum High-Density Lipoproteins, 430, 135-142. (1988)	
	172	Parker, et al., Proceedings of the National Academy of Sciences, Plasma High Density Lipoprotein is Increased in Man When Low Density Lipoprotein (LDL) is Lowered by LDL-Pheresis, 83, 777-781. (1986)	
	173	Paterno et al., Department of Clinical and Experimental Medicine, Reconstituted High-Density Lipoprotein Exhibits Neuroprotection in Two Rat Models of Stroke. (December 29, 2003)	
	174	Robert et al., Experientia, The Application of Sodium Deoxycholate and Sephacryl-200 for the Delipidation and Separation of High Density Lipoproteins, 38, 437-439. (1982)	
	175	Ryan, et al., Clinical Chemistry, An Improved Extraction Procedure for the Determination of Triglycerides and Cholesterol in Plasma or Serum, 13, 769-772. (1967)	
	176	Scanu et al., Analytical Biochemistry, Solubility in Aqueous Solutions of Ethanol of the Small Molecular Weight Peptides of the Serum Very Low Density and High Density Lipoproteins: Relevance to the Recovery Problem During Delipidation of Serum Lipoproteins, 44, 576-588. (1971)	
	177	Segrest et al., Journal of Biological Chemistry, A Detailed Molecular Belt Model for Apolipoprotein A-I in Discoidal High Density Lipoprotein, 274 (45), 31755-31758. (November 5, 1999)	
	178	Slater, et al., J. of Lipid Research, A Comparison of Delipidated Sera Used in Studies of Sterol Synthesis by Human Mononuclear Leukocytes, 20, 413-416. (1979)	
	179	Slater, et al., Atherosclerosis, The Effect of Delipidated High Density Lipoprotein on Human Leukocyte Sterol Synthesis, 35, 41-49. (1980)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Number	10/650,110
Filing Date	August 26, 2003
First Named Inventor	Yanhong Zhu
Group Art Unit	1646
Examiner Name	Not yet Assigned
Attorney Docket Number	13131-0292 (44378/287574)

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published

180	Thompson, et al., Lancet (LOS), Plasma Exchange in the Management of Homozygous Familial Hypercholesterolaemia, 1, 1208-1211. (1975)
181	Williams, et al., Proc. Natl. Acad. Sci. USA, Low Density Lipoprotein Receptor-Independent Hepatic Uptake of a Synthetic, Cholesterol-Scavenging Lipoprotein: Implications for the Treatment of Receptor-Deficient Atherosclerosis, 85, 242-246. (1988)
182	Williams et al., Biochim. Biophys. Act., Uptake of Endogenous Cholesterol by a Synthetic Lipoprotein , 875 (2), 183-194. (February 12, 1986)
183	Wong, et al, Journal of Lipid Research, Retention of gangliosides in serum delipidated by diisopropyl ether-1-butanol extraction, 24, 666-669. (1983)
184	Wormser, Henry, PSC3110 - Fall Semester 2002, Lipids.
185	Yokoyama, et al., Arteriosclerosis, Selective Removal of Low Density Lipoprotein by Plasmapheresis in Familial Hypercholesterolemia, 5, 613-622. (1985)
186	Zhang et al., Journal of Lipid Research, Characterization of phospholipids in a pre-alpha HDL: Selective Phospholipid Efflux with Apolipoprotein A-I. 39, 1601-1607. (1998)

Date
Considered

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.